Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved

Nuvation Bio Inc.

Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.
Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.
Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.
Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.
Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerry Wang

Chief Executive Officer of AnHeart Therapeutics

NUVB · Nuvation Bio Inc.

Effective: 2025-02-12
Filed: February 12, 2025, 6:59 PM ET

On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals

Departed

Jerry Wang

Member of the Board of Directors

NUVB · Nuvation Bio Inc.

Effective: 2025-02-11
Filed: February 12, 2025, 6:59 PM ET

Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..

Action: departed
Role: Chief Executive Officer of AnHeart Therapeutics

Exact text from the filing

On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.

View on SEC.gov

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-025099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.